Posted by Michael Wonder on 03 Nov 2021
Trastuzumab deruxtecan type II variation application validated by EMA for the treatment of HER2 positive advanced gastric cancer
3 November 2021 - Application based on DESTINY-Gastric01 and DESTINY-Gastric02 phase 2 trials.
Daiichi Sankyo today announced that the EMA has validated the type II variation application for trastuzumab deruxtecan, a HER2 directed antibody drug conjugate being jointly developed by Daiichi Sankyo and AstraZeneca, for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastro-esophageal junction adenocarcinoma who have received a prior anti-HER2-based regimen.
